Therapix Bio nabs rights to nasal drug delivery technology; shares up 4%

|About: Therapix Biosciences (TRPX)|By:, SA News Editor

Therapix Biosciences (TRPX +3.6%) inks a sublicense agreement with Hebrew University's Yissum Research Development Company for global exclusive rights to its nasal drug delivery technology for the nasal delivery of cannabinoids.

The technology facilitates the administration and effective nasal absorption of tetrahydrocannabinol (THC), the active ingredient in the drugs being developed by Therapix.